

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION APPOINTS CLINICAL ADVISORY BOARD

EMvision Medical Devices Limited (ASX:EMV) ("EMvision" or the "Company"), is pleased to announce the formation of its Clinical Advisory Board. The Advisory Board consists of several eminent medical and neurology experts: Prof Michael O'Sullivan, Dr Ken Mitchell, Dr David Cook, Dr James Walsham and Prof Stuart Crozier, who will serve as the Chairman.

The newly appointed Advisory Board will work closely with the EMvision Board and management team as it continues to advance its portable brain scanner program. Based in Brisbane, the group will provide expert input and guidance into EMvision's clinical, developmental and commercial strategy.

Dr Ron Weinberger, CEO, said, "We feel privileged to have attracted advisors with world-leading experience in diagnosing and treating neurological disorders, to join EMvision's advisory board. The group will assist in guiding our product development and delivering on our value-creation goals. The composition and Brisbane location of the group has been specifically engineered to aid in delivering a successful clinical trial program."

Professor Stuart Crozier (Chairman of Clinical Advisory Board) BE (Hons) MSc PhD DEng FTSE



The first appointment to the Committee is of Prof Stuart Crozier as Chairman. Professor Crozier is co-inventor of EMvision's underlying technology and the Director of Biomedical Engineering at the University of Queensland. Professor Crozier's advancements in MRI technology, having licenced them to GE Healthcare and Siemens Healthineers, are now central to more than 65% of all MRI machines manufactured since 1997 and have been used in billions of scans around the world. Professor Crozier brings a wealth of experience in developing new medical imaging systems and applications that have had a significant global impact.

Prof Crozier said "It is a pleasure to be involved with this Clinical Advisory Board. EMvision has assembled a set of very talented and experienced clinicians in the fields of Neurology, Interventional Neuroradiology and Critical Care. The board will no doubt grow in the future as the clinical targets expand. It is critically important that the clinical need drives the directions of the technology and not the other way around, in my view. The board will have a very important role in this regard as EMvision develops its new modality for diagnostic imaging."

Professor Michael O'Sullivan MA MB BS PhD FRCP FRACP




Professor O'Sullivan is a neuroscientist and neurologist in Brisbane. He is a professor and member of the Executive of the UQ Centre for Clinical Research and a Staff Specialist in Neurology at the Royal Brisbane and Women's Hospital. Here he participates in the hyperacute stroke and clot retrieval service, providing acute care to patients in Brisbane and much of central and northern Queensland. Prof O'Sullivan's research focus is translational in nature, promoting restoration of brain function after stroke.

His work utilises advanced imaging techniques and focuses on memory function, cognitive control, ageing and early cognitive decline and dementia. He co-chairs the Cognition Group of the International Stroke Recovery and Rehabilitation Roundtable. Professor O'Sullivan trained as an undergraduate in Cambridge, did specialist training in London, was a Medical Research Council Clinician Scientist Fellow from 2008-2012 and then academic lead for stroke at King's Health Partners in London.

Prof O'Sullivan said *"Stroke care is entering a new phase. For the last 2 decades, improvements in stroke care have focussed on building stroke units in centres of excellence for stroke. These now implement advanced imaging technology to deliver cutting edge interventions, such as 'clot retrieval'. But many strokes occur far from a specialist centre. A new phase will see mobile and portable technology move to the patient. We need advanced solutions beside the patient at the time of stroke, so that treatments can be delivered within the community without delay, and so that we can rapidly identify those patients that need to go to a centre. That vision of technology reaching patients wherever they are, on a global scale, is the reason I'm so excited to be part of EMvision."*

Dr Ken Mitchell MB BS FRANZCR



Dr Mitchell is a practising Interventional Neuroradiologist (CCINR accredited) who provides care, management and treatment of neurovascular disease, including stroke, in Brisbane. Dr Mitchell performs Endovascular Clot Retrieval in acute stroke that requires mechanical clot retrieval at the Royal Brisbane and Women's Hospital and other major Brisbane Hospitals. Dr Mitchell is also a Senior Lecturer at the University of Queensland. In addition to his work in more recent interventional Stroke care, Dr Mitchell has close to 30 years' experience in the management of brain and spine vascular disease including aneurysms and vascular malformations.

Dr Mitchell said *"In recent years, reperfusion therapies such as thrombolysis and endovascular thrombectomy for ischaemic stroke have dramatically reduced disability and transformed stroke management. These advances in stroke care have greatly increased the demand on interventional medical services and have highlighted the need for rapid, portable imaging, for better acute evaluation of the patient. I look forward to better outcomes for our patients by identifying those most suitable for the new treatments now available earlier."*

Dr David Cook MBBS FANZCA FCICM PhD



Dr Cook is a senior critical care specialist and anaesthetist at Brisbane's PA Hospital's Intensive Care Unit. His PhD in 2003 from the University of Queensland (UQ) Information Technology and Electrical Engineering school, developed prediction models using machine learning and sequential statistics. He is Associate Professor with UQ Faculty of Medicine and Adjunct Professor with Queensland University of Technology Science and Engineering Faculty. Dr Cook has published across a wide range of topics and disciplines including toxicology and pharmacology, biochemistry, statistics and modelling, epidemiology, process improvement and health economics, and has a research interest in integration of information from disparate sources and the measurement of "quality of knowledge".

Dr Cook said *"The last two years has seen EMvision technology advancing us towards the realisation of a novel imaging technology that will assist medical practitioners in making critical decisions, and critical interventions earlier, when time matters."*

Dr James Walsham MB ChB MRCP FCICM



Dr Walsham is a senior staff specialist at the Princess Alexandra Hospital in Brisbane. In his role as director of research within the ICU he is the site principal investigator in a wide range of research activities including large multicentre trials as well as industry sponsored trials. Dr Walsham completed his basic medical degree at Manchester University in the UK before moving to Australia where he completed his Intensive Care training in Queensland.

Dr Walsham said *"I'm excited to be involved in the development of EMvision's potentially disruptive new technology."*

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMvision Medical Devices

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMvision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.3 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.